Volume 94 Issue 15 | Latest News
Web Date: April 5, 2016

Gilead buys Nimbus’s NASH portfolio

$400 million deal adds ACC inhibitors to Gilead’s liver disease pipeline
Department: Business
Keywords: pharmaceuticals, biotech, NASH, liver disease

In a bid to strengthen its liver disease drug pipeline, Gilead Sciences will pay $400 million up front for Nimbus Therapeutics’ small molecules for nonalcoholic steatohepatitis (NASH), a liver disease that can lead to cirrhosis.

Currently, no drugs exist to treat NASH, which begins with fat deposits in the liver and can cause scar tissue to accumulate. Up to 5% of Americans have NASH and another 10–20% have fat in their liver, according to the . . .

To view the rest of this content, please log in with your ACS ID.

Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society